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mAb 17 .41 shed significantly fewer (P < 0.005) C. parvum oocysts than scid mice receiving isotype control mAb. Intestinal (but not gastric) infectivity scores were also reduced for scid mice treated with mAb 17.41 (P < 0.01).
The protozoal agent Cryptosporidium parvum infects intestinal epithelial cells of most mammalian species (10) . Immunocompetent humans infected with C. parvum experience diarrhea of limited duration followed by recovery within 7 to 21 days and resistance to reinfection. Immunocompromised humans develop persistent infections accompanied by severe, sometimes life-threatening diarrhea (7-11, 13, 18, 25) . Management of these patients is complicated by the absence of chemotherapeutic agents that are predictably effective in clearing C. parvum infection.
Given the importance of immune responses in controlling C parvum infection, we and others have produced monoclonal antibodies (mAbs) that neutralize the infectivity of merozoites and/or sporozoites, the two infectious stages of the organism (2, 5, 22, 26) . Investigators have shown that these antibodies protect suckling mice from initial infection (2, 5, 20, 22, 26, 28) and reduce the severity of persistent cryptosporidial infections in nude mice (4, 19) . Severe combined immune deficient (scid) mice infected with C. parvum have been used to study infection parameters and treatment protocols (14) (15) (16) 24 17 (experiment 2) days of mAb treatment, respectively. The stomach, ileum, cecum, and colon were examined histologically for the presence and number of C. parvum organisms. Tissue infectivity scores ranging from 0 to 3 were assigned to each anatomical site, as previously described (0, no organisms observed; 1, <33% of the mucosal epithelium parasitized; 2, 33 to 66% of the epithelium parasitized; 3, >66% of the epithelium parasitized) (23) . Results were analyzed with the Wilcoxon signed rank test to determine whether differences were significant (1) .
Excretion of C. parvum oocysts was readily detectable 4.4 weeks postinfection (Fig. 1) . Treatment with mAb began 6 weeks postinfection. An apparent reduction in oocyst excretion was noted at week 7, but the difference was not significant until 8 weeks postinfection (P = 0.014). By completion of the experiment at 8.4 weeks postinfection, treatment with mAb 17.41 substantially reduced oocyst excretion compared with excretion with the control mAb (P = 0.001).
Examination of tissue sections from treated and control mice substantiated the effect of mAb 17.41 on infection with C. parvum (Table 1) . Tissue infectivity scores were significantly lower for mice treated with mAb 17.41 (P = 0.0005, experiment 1; P = 0.007, experiment 2) compared with scores with the control mAb. However, results were influenced by the anatomical site of infection. C. parvum is not typically located in the gastric epithelium of immunocompetent mice (27) , but is routinely found there in scid mice (15) . C. parvum infection in the biliary system (4, 19) and stomach (present study). Both locations are sites of infection in patients with AIDS (3, 6, 12, 17, 21) . Therefore, treatment of persistent cryptosporidiosis in immunodeficient patients 
